article · International Journal of Nanomedicine
Combining alginate and chitosan into nanoparticle drug delivery systems provides an effective approach for delivering antibacterial therapeutics. These natural polysaccharides offer high biocompatibility for integration into the body. Reducing drug formulations to the nano-scale increases their surface area, which improves solubility in aqueous environments and enables extended drug release. Existing experimental evidence confirms that alginate-chitosan nanoparticles enhance antibacterial efficacy, demonstrated by broader zones of inhibition, improved minimum inhibitory concentrations, and faster bacterial reduction rates. These improvements stem from higher drug solubility, sustained release, and ionic attraction between the positively charged nanoparticles and teichoic acid within bacterial cell walls. Although laboratory findings are strong, clinical studies remain scarce, and no commercial antibacterial formulations currently use this delivery system, highlighting the need for clinical trials to validate their therapeutic potential.
Bacterial infections often demand sustained treatment, but many antibacterial compounds suffer from poor solubility and short lifespans in the body. Using biocompatible, natural materials to form nano-scale carriers can improve how effectively these medications target bacteria and release over time. Validating these formulations clinically could help develop more potent treatments against bacterial pathogens.
This technology could enable pharmaceutical developers to produce enhanced antibacterial formulations with extended release and improved solubility. However, it remains at an early stage of development. Because there are currently no marketed antibacterial drugs employing this alginate-chitosan system and clinical trials are limited, substantial clinical efficacy validation is required before these delivery carriers can reach commercial healthcare markets.
AI-generated from the published abstract. Always read the original work before citing.
Nanoparticle systems integrating alginate and chitosan emerge as a promising avenue to tackle challenges in leveraging the potency of pharmacological active agents. Owing to their intrinsic properties as polysaccharides, alginate and chitosan, exhibit remarkable biocompatibility, rendering them conducive to bodily integration. By downsizing drug particles to the nano-scale, the system enhances drug solubility in aqueous environments by augmenting surface area. Additionally, the system orchestrates extended drug release kinetics, aligning well with the exigencies of chronic drug release requisite for antibacterial therapeutics. A thorough scrutiny of existing literature underscores a wealth of evidence supporting the utilization of the alginate-chitosan nanoparticle system for antibacterial agent delivery. Literature reviews present abundant evidence of the utilization of nanoparticle systems based on a combination of alginate and chitosan for antibacterial agent delivery. Various experiments demonstrate enhanced antibacterial efficacy, including an increase in the inhibitory zone diameter, improvement in the minimum inhibitory concentration, and an enhancement in the bacterial reduction rate. This enhancement in efficacy occurs due to mechanisms involving increased solubility resulting from particle size reduction, prolonged release effects, and enhanced selectivity towards bacterial cell walls, stemming from ionic interactions between positively charged particles and teichoic acid on bacterial cell walls. However, clinical studies remain limited, and there are currently no marketed antibacterial drugs utilizing this system. Hence, expediting clinical efficacy validation is crucial to maximize its benefits promptly.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2147/ijn.s469572
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
